Navigation Links
Device May Offer Alternative to Warfarin for Arrhythmia
Date:8/14/2009

Implantation in people at risk for stroke could reduce medication use, study suggests

FRIDAY, Aug. 14 (HealthDay News) -- Closing the heart's left atrial appendage could offer an alternative to long-term warfarin treatment for people with non-valvular atrial fibrillation who are at risk for stroke, according to a new study.

Atrial fibrillation, the most common type of irregular heartbeat, causes the upper chambers of the heart to quiver. This can cause blood to pool and form clots in the left atrial appendage (LAA), a long, tubular structure connected to the left atrial cavity. More than 90 percent of atrial blood clots in people with non-valvular atrial fibrillation may originate in the LAA, according to background information in the study.

The study included 463 people who underwent percutaneous implantation of a device, known as the Watchman, to close off the LAA. Their outcomes were compared with those of 244 people who continued long-term treatment with warfarin.

The researchers determined the effectiveness of the treatments by assessing the occurrence, during an average follow-up of 18 months, of strokes, death from cardiovascular causes and systemic embolisms (blood clots that go somewhere other than the brain). They also totaled the occurrence of such serious problems as major bleeding, pericardial effusion (accidental puncture of the heart causing fluid collection in the heart sac) and clots caused by the implanted device.

After 1,065 patient-years of follow-up, there were 3.0 such occurrences per 100 patient-years among those who'd had the device implanted, compared with 4.9 in the warfarin group, for a risk reduction of 38 percent. But people in the device group had more serious safety events -- 7.4 events per 100 patient-years versus 4.4 events in the warfarin group, the researchers found.

"The efficacy of percutaneous closure of the LAA with this device was non-inferior to that of w
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
2. Worlds First Emergency Medical Device Franchise Launches eMed-Alert
3. BrainScope(TM) Receives FDA Clearance for Portable EEG Device
4. Inaugural Medical Device Connectivity Conference & Exhibition to Focus on Connecting Medical Devices to People, Workflow and Information Systems
5. X4 Labs to Create Solid Gold Male Enhancement Device for Rich Saudi Man
6. ThermoGenesis Announces Launch of Res-Q System; New Device Expands Companys Presence in Bone Marrow Sector
7. ReGen Biologics Clarifies Recent Press about the Menaflex Device
8. Validation & Compliance Institute, LLC, to Provide Medical Device Regulatory Training for the University of Michigans Medical Innovation Center
9. New Surgical Device Revolutionizes Face Lifts, Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time, Less Pain and Fewer Bruises
10. CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices
11. Valve Repair First in New England Done With Robotic Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Device May Offer Alternative to Warfarin for Arrhythmia
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... 03, 2015 , ... The art of preparing and cooking food comes naturally ... a young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that ... from My Persian Kitchen with the world. , Since Americans tend to be undereducated ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration ... is similar to deoxycholic acid, which occurs naturally in the body and helps absorb ... treat this area of the body. These are invasive procedures and very expensive for ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director of ... The new facility is licensed under Dignity Health Arizona General Hospital , ... an excellent leader and will ensure our new freestanding emergency room delivers the highest ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... provider of medical information, risk management and investigative services, has introduced a ... toward focused, expert information solutions that improve business outcomes for its customers. ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... (30), a,quadriplegic patient who is dependent on a respirator since ... LASIK procedure performed,by Drs. Jeffrey and Joseph Dello Russo. Eric ... his neck and severing his spinal cord. Since,that day, he ... his body below his upper neck down and is able ...
... Names Kaiser Permanente "Highest in,Member Satisfaction" Among All ... Kaiser Permanente Colorado is the,top-ranked commercial health plan ... a joint ranking by U.S. News & World ... To view the Multimedia News Release, go ...
... survival rates , , FRIDAY, Nov. 7 (HealthDay News) -- ... adults requiring surgery to repair a congenital heart defect, ... occurs when there,s abnormal pre-birth development of the heart ... analyzed a national database to identify 30,250 congenital heart ...
... October 31, 2008 -- Children under the age of three ... behavioral or developmental problems later compared to children who had ... at Columbia University Mailman School of Public Health and the ... children who were born into the New York State Medicaid ...
... Will Be Celebrity Host of Show at Nassau Coliseum, ... today,announced the first of its 2009 Concert Series -- a ... Cancer Research,Foundation., The show will be held on February ... go on sale Monday, November 10th at 10am,through Ticketmaster.com or ...
... National Health Science Summit, DALLAS, Nov. 7 ... today announced Dr. Valentin Fuster, director of,Mount Sinai ... Prize.,The Prize was presented to Dr. Fuster by ... Health Science Summit held on,November 7, 2008 in ...
Cached Medicine News:Health News:Historic LASIK Surgery Performed on Quadriplegic Patient to Preserve his Communication Abilities 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 2Health News:Audio: Kaiser Permanente is Colorado's Top Commercial and Medicare Plan on U.S. News & World Report/NCQA 'America's Best Health Plans' List 3Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:General anesthesia for hernia surgery in children and risk of later developmental problems 2Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3
(Date:8/3/2015)... , August 3, 2015 ... announced today that it has acquired ... Inc. for $300 million. With the acquisition, Shire ... drops combining 0.6% povidone iodine (PVP-I) and 0.1% ... treatment of infectious conjunctivitis, an ocular surface condition ...
(Date:8/2/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... to discover and develop antisense therapies for cardiovascular, ... on a broad existing relationship between the two ... therapeutic areas using novel RNA-targeted treatments. It also ... antisense technology to diseases of the kidney. ...
(Date:8/2/2015)... Texas , Aug. 3, 2015  Lexicon ... that the pivotal TELESTAR Phase 3 clinical trial ... oral telotristat etiprate in treating cancer patients with ... the current standard of care. Telotristat etiprate was ... Prize-winning technology, and is the company,s first discovery ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... 7, 2010 Where do you start when trying to ... ), an independent nonprofit that researches the best approaches to ... release of its 5th annual list of Top 10 ... free download with registration, the list features the ...
... Research Group (MRG), the global authority on medical technology ... the US clot management device market.   ... report provides important insight into the device-based treatments ... of medical device manufacturers in this field. The report ...
Cached Medicine Technology:ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 2ECRI Institute Releases 'Top 10 Health Technology Hazards for 2011' 3Millennium Research Group to Release Their Latest US Clot Management Data 2
Invacare 5 Oxygen Concentrator with Sens O2, 230 VAC - Intl....
... Nine out of ten peptic ulcers ... can deliver improved patient care while the ... that fits the staffing requirements of waived ... Facilities: the most sensitive CLIA-waived rapid H. ...
... the Japanese market:, ,QuietLife 3 ... low-power-consumption, high-performance oxygen concentrator for home ... in an attractive, lightweight (26 kg) ... to meet the requirements of the ...
... Oxygen Concentrator is a low decibel, low ... oxygen for prescriptions up to 5 liters ... running concentrator at <40 dBA, this unit ... Concentrators are also an economical and safe ...
Medicine Products: